This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Understanding the roles TIGIT targeting drugs play in cancer immunotherapy and efficacy compared to PD-1 inhibitors


Who's the expert?

Institution: University of Pittsburgh

  • Professor of Medicine, Immunology and Dermatology and Co-leader of the Cancer Immunology and Immunotherapy Program at University of Pittsburgh.
  • Research focuses on translational cancer immunotherapy and mechanisms of tumor-induced immune cell dysfunction, including the role of multiple inhibitory receptor pathways (PD-1, Tim-3, BTLA and TIGIT)
  • Authored over 50 publications in the cancer immunology space.

Interview Goal
This conversation fill focus on discussing how TIGIT targeting drugs fit into cancer immunotherapy. We will also take a closer look at the necessity of co-inhibitory receptors that help regulate T-cell responses including PD-1, CTLA-4, and LAG-3.

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.


*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.